** Shares in Elekta EKTAb.ST rise more than 10% after the Swedish radiation therapy equipment maker reported Q2 EBIT 7.5% above consensus
** "The Q2 beat at the adjusted EBIT level implies c.1.5% upgrades to FY25/26 adjusted EBIT estimates," J.P. Morgan analysts say in a note
** Elekta also presented a new operational structure, which it expects to generate at least SEK 500 million ($52.5 million) in annual savings from Q1 2026/27 and eliminate around 450 positions
** Jefferies analysts are concerned by a new SEK 2.2 billion order cancellation, which reduces the backlog by 6%, and questions the company's ability to sustain top-line momentum
** Elekta reiterated its full-year 2025/26 outlook
** The company's shares are on track for their best day since August 2020 if the gains hold
($1 = 9.5198 Swedish crowns)
(Reporting by Agnieszka Olenska)
((Agnieszka.Olenska@thomsonreuters.com;))